Adjuvant chemotherapy in stage IB non-small cell lung cancer: if, when, how?

Short review

DOI: 10.1007/s12254-008-0015-4

Cite this article as:
Dediu, M. memo (2008) 1: 61. doi:10.1007/s12254-008-0015-4


Adjuvant chemotherapy is established as a standard of care for resectable non-small cell lung cancer. However, this indication remains controversial for the stage IB as the results of the randomized trials and meta-analysis are obscuring on this issue. Moreover, the updated international guidelines do not prescribe the regular use of this strategy in stage IB. The aim of this paper is to review the current evidences regarding the benefit of adjuvant CT in this setting, and to provide clinical hints, which can lend a helping hand to the clinicians and their patients to take the right decision in this particular scenario.


Adjuvant chemotherapy Stage IB Risk factors NSCLC 

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Medical Oncology DepartmentInstitute of Oncology BucharestBucharestRomania

Personalised recommendations